

CITATION REPORT

List of articles citing

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

DOI: 10.1111/dom.12250

Diabetes, Obesity and Metabolism, 2014, 16, 366-75.

Source: <https://exaly.com/paper-pdf/58899966/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
39	The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. <i>Journal of Medical Economics</i> , 2014 , 17, 827-36	2.4	5
38	New forms of insulin and insulin therapies for the treatment of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 638-52	18.1	61
37	Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain. <i>Diabetes Therapy</i> , 2015 , 6, 593-610	3.6	4
36	Clinical use of insulin degludec. <i>Diabetes Research and Clinical Practice</i> , 2015 , 109, 19-31	7.4	43
35	Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. <i>Journal of Medical Economics</i> , 2015 , 18, 56-68	2.4	29
34	Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice. <i>Journal of Comparative Effectiveness Research</i> , 2015 , 4, 279-286	2.1	1
33	Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation. <i>Journal of Medical Economics</i> , 2015 , 18, 96-105	2.4	21
32	Concentrated insulins: the new basal insulins. <i>Therapeutics and Clinical Risk Management</i> , 2016 , 12, 389-400	4.9	27
31	Are the most recent basal insulins really the most innovative?. <i>Medicina Clínica (English Edition)</i> , 2016 , 147, 297-299	0.3	
30	[Are the most recent basal insulins really the most innovative?]. <i>Medicina Clínica</i> , 2016 , 147, 297-9	1	
29	Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective. <i>Diabetes Therapy</i> , 2016 , 7, 809-823	3.6	3
28	A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. <i>Diabetic Medicine</i> , 2016 , 33, 478-87	3.5	29
27	Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2017 , 8, 275-291	3.6	23
26	Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. <i>Current Medical Research and Opinion</i> , 2017 , 33, 647-655	2.5	10
25	Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 587-595	2.2	15
24	Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine. <i>Current Medical Research and Opinion</i> , 2017 , 33, 231-238	2.5	5
23	Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. <i>Pharmacoeconomics</i> , 2017 , 35, 141-162	4.4	10

22	A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. <i>Journal of Medical Economics</i> , 2017 , 20, 213-220	2.4	11
21	Quality-of-life and treatment satisfaction in actual clinical practice of patients with Type 1 diabetes mellitus (T1DM) and hypoglycemia treated with insulin degludec. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1053-1059	2.5	4
20	DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. <i>Diabetes Therapy</i> , 2018 , 9, 1217-1232	3.6	10
19	Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia. <i>Diabetes Therapy</i> , 2018 , 9, 1201-1216	3.6	7
18	Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. <i>Journal of Medical Economics</i> , 2018 , 21, 144-151	2.4	5
17	Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. <i>Diabetes Therapy</i> , 2018 , 9, 1919-1930	3.6	10
16	What is innovation in the area of medicines? The example of insulin and diabetes. <i>Diabetic Medicine</i> , 2019 , 36, 1528-1529	3.5	0
15	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). <i>Applied Health Economics and Health Policy</i> , 2019 , 17, 615-627	3.4	5
14	Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China. <i>Diabetes Therapy</i> , 2019 , 10, 1969-1984	3.6	3
13	Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy. <i>Diabetes Therapy</i> , 2019 , 10, 1347-1356	3.6	3
12	Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1706-1714	6.7	3
11	Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK. <i>BMJ Open Diabetes Research and Care</i> , 2019 , 7, e000664	4.5	6
10	Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria. <i>BMC Endocrine Disorders</i> , 2019 , 19, 132	3.3	3
9	Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials. <i>Diabetes and Metabolism</i> , 2020 , 46, 83-88	5.4	
8	Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy. <i>European Journal of Health Economics</i> , 2020 , 21, 1179-1196	3.6	2
7	Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K. <i>Diabetes Care</i> , 2020 , 43, 2411-2417	14.6	11
6	Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analogues. <i>Diabetes/Metabolism Research and Reviews</i> , 2020 , 36, e3329	7.5	5
5	Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial. <i>Advances in Therapy</i> , 2020 , 37, 2413-2426	4.1	5

4	Basal Insulin Inadequacy versus Failure - Using Appropriate Terminology. <i>European Endocrinology</i> , 2015 , 11, 79-80	3-4	3
3	Efficacy, safety and clinical use of newer basal insulins analogs. <i>Endocrinology&Metabolism International Journal</i> , 2018 , 6,	0	
2	Cost-Utility Analysis of Semaglutide for type 2 diabetes after its Addition to the National Medical Insurance System in China.		0
1	Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.		1